Ginkgo Biloba Extract
Drug Allergy
Dongzhimen Hospital, BeijingUNKNOWNPhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Drug Allergy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Qinggongshoutao Bolus Dongzhimen Hospital, Beijing | Phase 4 | BB |
Thalidomide Chang Gung Memorial Hospital | Phase 2 | B |
(1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil 1:4 Chang Gung Memorial Hospital | Phase 2 | B |
Hydrocortisone University Medical Center Groningen | Phase 2 | CCC |
Apomorphinum University Medical Center Groningen | Phase 2 | CCC |
View all 17 →
Same molecule, other indications
Ginkgo Biloba Extract is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →